Supriya Lifescience
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
** Supriya Lifescience SPRL.NS shares fall nearly 6% to 923.6 rupees
** Stock on track for worst intraday pct fall in over a month
** Pharmaceutical co says Customs Department is probing General Manager (Sales & Marketing) Sreekant Sreedharan under the Narcotic Drugs and Psychotropic Substances Act
** Co says probe over alleged procedural lapse in an export transaction involving an identified product; officer under judicial detention
** YTD, up to last close, stock up 25%
(Reporting by Payel Das in Bengaluru)
** Supriya Lifescience SPRL.NS shares fall nearly 6% to 923.6 rupees
** Stock on track for worst intraday pct fall in over a month
** Pharmaceutical co says Customs Department is probing General Manager (Sales & Marketing) Sreekant Sreedharan under the Narcotic Drugs and Psychotropic Substances Act
** Co says probe over alleged procedural lapse in an export transaction involving an identified product; officer under judicial detention
** YTD, up to last close, stock up 25%
(Reporting by Payel Das in Bengaluru)
June 2 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE - LOTE FACILITY RECEIVES USFDA EIR WITH VOLUNTARY ACTION INDICATED CLASSIFICATION
Source text: ID:nBSE6NQtHf
Further company coverage: SPRL.NS
(([email protected];))
June 2 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE - LOTE FACILITY RECEIVES USFDA EIR WITH VOLUNTARY ACTION INDICATED CLASSIFICATION
Source text: ID:nBSE6NQtHf
Further company coverage: SPRL.NS
(([email protected];))
May 27 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
MARCH-QUARTER PROFIT 742.3 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 2.77 BILLION RUPEES
DECLARES DIVIDEND OF 1 RUPEE PER SHARE
Source text: [ID:]
Further company coverage: SPRL.NS
(([email protected];))
May 27 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
MARCH-QUARTER PROFIT 742.3 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 2.77 BILLION RUPEES
DECLARES DIVIDEND OF 1 RUPEE PER SHARE
Source text: [ID:]
Further company coverage: SPRL.NS
(([email protected];))
April 22 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
US FDA INSPECTS SUPRIYA LIFESCIENCE LOTE FACILITY FROM FEB 2 TO FEB 6, 2026
US FDA ISSUES FORM 483 WITH ONE MINOR OBSERVATION TO SUPRIYA LIFESCIENCE
RECEIVES EIR INDICATING VOLUNTARY ACTION INDICATED (VAI)
Source text: ID:nNSEbX2QY0
Further company coverage: SPRL.NS
(([email protected];;))
April 22 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
US FDA INSPECTS SUPRIYA LIFESCIENCE LOTE FACILITY FROM FEB 2 TO FEB 6, 2026
US FDA ISSUES FORM 483 WITH ONE MINOR OBSERVATION TO SUPRIYA LIFESCIENCE
RECEIVES EIR INDICATING VOLUNTARY ACTION INDICATED (VAI)
Source text: ID:nNSEbX2QY0
Further company coverage: SPRL.NS
(([email protected];;))
Feb 9 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE DEC-QUARTER PROFIT 496.8 MILLION RUPEES
SUPRIYA LIFESCIENCE DEC-QUARTER REVENUE FROM OPERATIONS 2.06 BILLION RUPEES
Source text: ID:nnAZN4SFL7Z
Further company coverage: SPRL.NS
(([email protected];))
Feb 9 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE DEC-QUARTER PROFIT 496.8 MILLION RUPEES
SUPRIYA LIFESCIENCE DEC-QUARTER REVENUE FROM OPERATIONS 2.06 BILLION RUPEES
Source text: ID:nnAZN4SFL7Z
Further company coverage: SPRL.NS
(([email protected];))
Oct 1 (Reuters) - Supriya Lifescience SPRL.NS:
COMPLETION OF WHO GMP AUDIT AT AMBERNATH FACILITY
WHO ISSUES WHO-GMP CERTIFICATE FOR AMBERNATH FACILITY
Source text: ID:nBSEbwl5Z7
Further company coverage: SPRL.NS
(([email protected];))
Oct 1 (Reuters) - Supriya Lifescience SPRL.NS:
COMPLETION OF WHO GMP AUDIT AT AMBERNATH FACILITY
WHO ISSUES WHO-GMP CERTIFICATE FOR AMBERNATH FACILITY
Source text: ID:nBSEbwl5Z7
Further company coverage: SPRL.NS
(([email protected];))
Jan 24 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
DEC-QUARTER PROFIT 467.8 MILLION RUPEES
DEC-QUARTER REVENUE FROM OPERATIONS 1.86 BILLION RUPEES
Source text: [ID:]
Further company coverage: SPRL.NS
(([email protected];;))
Jan 24 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
DEC-QUARTER PROFIT 467.8 MILLION RUPEES
DEC-QUARTER REVENUE FROM OPERATIONS 1.86 BILLION RUPEES
Source text: [ID:]
Further company coverage: SPRL.NS
(([email protected];;))
** Supriya Lifescience SPRL.NS rises 4.6% to 750.50 rupees
** Pharma co inaugurates new multipurpose Active Pharmaceutical Ingredients production block near Maharashtra's Chiplun
** Says new block will increase site's capacity by more than 55%
** Stock snaps three-session losing streak
** SPRL up ~139% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Supriya Lifescience SPRL.NS rises 4.6% to 750.50 rupees
** Pharma co inaugurates new multipurpose Active Pharmaceutical Ingredients production block near Maharashtra's Chiplun
** Says new block will increase site's capacity by more than 55%
** Stock snaps three-session losing streak
** SPRL up ~139% YTD
(Reporting by Vijay Malkar)
(([email protected];))
Dec 17 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
INAUGURATES MODULE E PRODUCTION BLOCK
NEW FACILITY DEVELOPED WITH 1.25 BILLION RUPEES INVESTMENT
Source text: ID:nBSE5Sb7gX
Further company coverage: SPRL.NS
(([email protected];;))
Dec 17 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
INAUGURATES MODULE E PRODUCTION BLOCK
NEW FACILITY DEVELOPED WITH 1.25 BILLION RUPEES INVESTMENT
Source text: ID:nBSE5Sb7gX
Further company coverage: SPRL.NS
(([email protected];;))
Dec 9 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD - GETS APPROVAL FROM BRAZIL'S ANVISA FOR ESKETAMINE HYDROCHLORIDE
SUPRIYA LIFESCIENCE - DEVELOPED TECHNIQUE FOR LOW-COST MANUFACTURING OF ATORVASTATIN
Source text: ID:nBSE3X3Dp5
Further company coverage: SPRL.NS
(([email protected];))
Dec 9 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD - GETS APPROVAL FROM BRAZIL'S ANVISA FOR ESKETAMINE HYDROCHLORIDE
SUPRIYA LIFESCIENCE - DEVELOPED TECHNIQUE FOR LOW-COST MANUFACTURING OF ATORVASTATIN
Source text: ID:nBSE3X3Dp5
Further company coverage: SPRL.NS
(([email protected];))
** Shares of Supriya Lifescience SPRL.NS climb 4% to 576 rupees; set for fifth straight session of gains
** Drugmaker's Q2 consolidated profit after tax nearly doubles to 461.5 mln rupees ($5.4 mln); rev rises ~19%
** YTD, SPRL gains 82%
($1 = 84.0775 Indian rupees)
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
** Shares of Supriya Lifescience SPRL.NS climb 4% to 576 rupees; set for fifth straight session of gains
** Drugmaker's Q2 consolidated profit after tax nearly doubles to 461.5 mln rupees ($5.4 mln); rev rises ~19%
** YTD, SPRL gains 82%
($1 = 84.0775 Indian rupees)
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
Oct 28 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD SEPT-QUARTER PROFIT 461.5 MILLION RUPEES
SUPRIYA LIFESCIENCE LTD SEPT-QUARTER REVENUE FROM OPERATIONS 1.66 BILLION RUPEES
Source text: ID:nBSE6xzypD
Further company coverage: SPRL.NS
(([email protected];))
Oct 28 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD SEPT-QUARTER PROFIT 461.5 MILLION RUPEES
SUPRIYA LIFESCIENCE LTD SEPT-QUARTER REVENUE FROM OPERATIONS 1.66 BILLION RUPEES
Source text: ID:nBSE6xzypD
Further company coverage: SPRL.NS
(([email protected];))
** Shares of Supriya Lifescience SPRL.NS rise as much as 9.5% to 492.5 rupees, highest since April 11, 2022
** SPRL eyes fourth consecutive session of gains
** The pharma co reported a 57% rise in Q1 profit, rev from ops up 22% Y/Y
** More than 2 mln shares change hands, 4.7x its 30-day avg
** Stock up 53% so far this year vs a 32% rise in Nifty Pharma Index .NIPHARM
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of Supriya Lifescience SPRL.NS rise as much as 9.5% to 492.5 rupees, highest since April 11, 2022
** SPRL eyes fourth consecutive session of gains
** The pharma co reported a 57% rise in Q1 profit, rev from ops up 22% Y/Y
** More than 2 mln shares change hands, 4.7x its 30-day avg
** Stock up 53% so far this year vs a 32% rise in Nifty Pharma Index .NIPHARM
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
May 28 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD - CHANGE IN DESIGNATION OF SALONI WAGH AS MD
SUPRIYA LIFESCIENCE LTD - CHANGE IN DESIGNATION OF SALONI WAGH AS JOINT MD
Source text for Eikon: ID:nBSE51dvXs
Further company coverage: SPRL.NS
(([email protected];))
May 28 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD - CHANGE IN DESIGNATION OF SALONI WAGH AS MD
SUPRIYA LIFESCIENCE LTD - CHANGE IN DESIGNATION OF SALONI WAGH AS JOINT MD
Source text for Eikon: ID:nBSE51dvXs
Further company coverage: SPRL.NS
(([email protected];))
** Shares of Supriya Lifescience SPRL.NS up 7.1% at 333 rupees, highest price since Sept. 26, 2022
** Pharma ingredients maker's Q3 profit surged 3.1X YoY
** Stock on track for best day since Dec. 22, 2023
** Stock logs most active session since Dec. 26, 2023
** Rival pure-play API makers Glenmark Life Sciences GLEM.NS and Granules India GRAN.NS also posted Q3 profit climbs
(Reporting by Varun Vyas in Bengaluru)
** Shares of Supriya Lifescience SPRL.NS up 7.1% at 333 rupees, highest price since Sept. 26, 2022
** Pharma ingredients maker's Q3 profit surged 3.1X YoY
** Stock on track for best day since Dec. 22, 2023
** Stock logs most active session since Dec. 26, 2023
** Rival pure-play API makers Glenmark Life Sciences GLEM.NS and Granules India GRAN.NS also posted Q3 profit climbs
(Reporting by Varun Vyas in Bengaluru)
Feb 7 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
DEC-QUARTER PROFIT 297.9 MILLION RUPEES VERSUS PROFIT 95.2 MILLION RUPEES
DEC-QUARTER REVENUE FROM OPERATIONS 1.40 BILLION RUPEES VERSUS 1.05 BILLION RUPEES
APPROVED CAPITAL EXPENDITURE PLAN AT AMBERNATH SITE FOR CDMO FACILITY
Source text for Eikon: ID:nBSE706RjC
Further company coverage: SPRL.NS
(([email protected];))
Feb 7 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
DEC-QUARTER PROFIT 297.9 MILLION RUPEES VERSUS PROFIT 95.2 MILLION RUPEES
DEC-QUARTER REVENUE FROM OPERATIONS 1.40 BILLION RUPEES VERSUS 1.05 BILLION RUPEES
APPROVED CAPITAL EXPENDITURE PLAN AT AMBERNATH SITE FOR CDMO FACILITY
Source text for Eikon: ID:nBSE706RjC
Further company coverage: SPRL.NS
(([email protected];))
Jan 5 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
RECEIVED GMP CERTIFICATION FROM ANVISA BRAZIL
LOTE FACTORY PASSED BRAZILIAN GMP INSPECTION WITH "ZERO" OBSERVATION IN TERMS OF COMPLIANCE
Source text for Eikon: ID:nBSE1yGk7D
Further company coverage: SPRL.NS
(([email protected];;))
Jan 5 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
RECEIVED GMP CERTIFICATION FROM ANVISA BRAZIL
LOTE FACTORY PASSED BRAZILIAN GMP INSPECTION WITH "ZERO" OBSERVATION IN TERMS OF COMPLIANCE
Source text for Eikon: ID:nBSE1yGk7D
Further company coverage: SPRL.NS
(([email protected];;))
Nov 7 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD SEPT-QUARTER PROFIT 238.8 MILLION RUPEES VERSUS 168.6 MILLION RUPEES
SUPRIYA LIFESCIENCE LTD SEPT-QUARTER REVENUE FROM OPERATIONS 1.40 BILLION RUPEES VERSUS 1.12 BILLION RUPEES
Source text for Eikon: ID:nNSE1J0Wtz
Further company coverage: SPRL.NS
(([email protected];))
Nov 7 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD SEPT-QUARTER PROFIT 238.8 MILLION RUPEES VERSUS 168.6 MILLION RUPEES
SUPRIYA LIFESCIENCE LTD SEPT-QUARTER REVENUE FROM OPERATIONS 1.40 BILLION RUPEES VERSUS 1.12 BILLION RUPEES
Source text for Eikon: ID:nNSE1J0Wtz
Further company coverage: SPRL.NS
(([email protected];))
Nov 6 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD SIGNS AGREEMENT WITH KALINGA INSTITUTE OF TECHNOLOGY
Source text for Eikon: ID:nNSEb92j7p
Further company coverage: SPRL.NS
(([email protected];;))
Nov 6 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD SIGNS AGREEMENT WITH KALINGA INSTITUTE OF TECHNOLOGY
Source text for Eikon: ID:nNSEb92j7p
Further company coverage: SPRL.NS
(([email protected];;))
Oct 23 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SIGNS AGREEMENT WITH KALINGA INSTITUTE OF TECHNOLOGY
SIGNS AGREEMENT WITH KALINGA INSTITUTE OF TECHNOLOGY FOR DEVELOPMENT OF ORAL CANCER DETECTION KIT
Source text for Eikon: ID:nBSE6yL4V0
Further company coverage: SPRL.NS
(([email protected];))
Oct 23 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SIGNS AGREEMENT WITH KALINGA INSTITUTE OF TECHNOLOGY
SIGNS AGREEMENT WITH KALINGA INSTITUTE OF TECHNOLOGY FOR DEVELOPMENT OF ORAL CANCER DETECTION KIT
Source text for Eikon: ID:nBSE6yL4V0
Further company coverage: SPRL.NS
(([email protected];))
** Shares of Supriya Lifesciences SPRL.NS up as much as 3.75% at 289 rupees, their highest since Nov. 7
** Drugmaker on Thursday posted a 13% climb in Q1 profit, while revenue rose more than 30%
** More than 361,000 shares changed hands by 10:23 a.m. IST, 1.2x 30-day avg
** YTD, stock is up ~20%
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
** Shares of Supriya Lifesciences SPRL.NS up as much as 3.75% at 289 rupees, their highest since Nov. 7
** Drugmaker on Thursday posted a 13% climb in Q1 profit, while revenue rose more than 30%
** More than 361,000 shares changed hands by 10:23 a.m. IST, 1.2x 30-day avg
** YTD, stock is up ~20%
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
Aug 3 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
INDIA'S SUPRIYA LIFESCIENCE JUNE-QUARTER PROFIT 285.1 MILLION RUPEES VERSUS PROFIT 252.5 MILLION RUPEES
SUPRIYA LIFESCIENCE LTD JUNE-QUARTER REVENUE FROM OPERATIONS 1.32 BILLION RUPEES VERSUS 1.01 BILLION RUPEES
Source text for Eikon: ID:nBSE6Rt3MX
Further company coverage: SPRL.NS
(([email protected];))
Aug 3 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
INDIA'S SUPRIYA LIFESCIENCE JUNE-QUARTER PROFIT 285.1 MILLION RUPEES VERSUS PROFIT 252.5 MILLION RUPEES
SUPRIYA LIFESCIENCE LTD JUNE-QUARTER REVENUE FROM OPERATIONS 1.32 BILLION RUPEES VERSUS 1.01 BILLION RUPEES
Source text for Eikon: ID:nBSE6Rt3MX
Further company coverage: SPRL.NS
(([email protected];))
Aug 2 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
CO, PLASMA NUTRITION, INC ANNOUNCE COLLABORATION IN PROTEIN TECHNOLOGY
Source text for Eikon: ID:nBSE8QrJXc
Further company coverage: SPRL.NS
(([email protected];))
Aug 2 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
CO, PLASMA NUTRITION, INC ANNOUNCE COLLABORATION IN PROTEIN TECHNOLOGY
Source text for Eikon: ID:nBSE8QrJXc
Further company coverage: SPRL.NS
(([email protected];))
May 26 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
MARCH-QUARTER PROFIT 382.3 MILLION RUPEES VERSUS 462.1 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 1.42 BILLION RUPEES VERSUS 1.81 BILLION RUPEES
Source text for Eikon: ID:nBSE3gxBk5
Further company coverage: SPRL.NS
(([email protected];))
May 26 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
MARCH-QUARTER PROFIT 382.3 MILLION RUPEES VERSUS 462.1 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 1.42 BILLION RUPEES VERSUS 1.81 BILLION RUPEES
Source text for Eikon: ID:nBSE3gxBk5
Further company coverage: SPRL.NS
(([email protected];))
May 24 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD - EXECUTED LONG- TERM SUPPLY AND SALES AGREEMENT WITH LEADING COMPANY IN EUROPE FOR SUPPLY OF ACTIVE PHARMACEUTICAL INGREDIENT
SUPRIYA LIFESCIENCE LTD - AGREEMENT FOR A PERIOD OF 10 YEARS
SUPRIYA LIFESCIENCE LTD - BUSINESS POTENTIAL WOULD BE APPROXIMATELY 400 MILLION RUPEES PER YEAR AT ITS PEAK
SUPRIYA LIFESCIENCE LTD - PEAK VOLUMES ARE EXPECTED TO HAPPEN IN FY 27
Source text for Eikon: ID:nBSE67sV64
Further company coverage: SPRL.NS
(([email protected];))
May 24 (Reuters) - Supriya Lifescience Ltd SPRL.NS:
SUPRIYA LIFESCIENCE LTD - EXECUTED LONG- TERM SUPPLY AND SALES AGREEMENT WITH LEADING COMPANY IN EUROPE FOR SUPPLY OF ACTIVE PHARMACEUTICAL INGREDIENT
SUPRIYA LIFESCIENCE LTD - AGREEMENT FOR A PERIOD OF 10 YEARS
SUPRIYA LIFESCIENCE LTD - BUSINESS POTENTIAL WOULD BE APPROXIMATELY 400 MILLION RUPEES PER YEAR AT ITS PEAK
SUPRIYA LIFESCIENCE LTD - PEAK VOLUMES ARE EXPECTED TO HAPPEN IN FY 27
Source text for Eikon: ID:nBSE67sV64
Further company coverage: SPRL.NS
(([email protected];))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Supriya Lifescience do?
Supriya Lifescience Limited is an Indian manufacturer and supplier of APIs, focusing on research and development. They offer a diverse range of niche APIs for different therapeutic segments and have a significant market presence globally.
Who are the competitors of Supriya Lifescience?
Supriya Lifescience major competitors are Acutaas Chemicals, Aether Industries, Aarti Pharmalabs, IOL Chem & Pharma, SMS Pharmaceuticals, Aarti Drugs, Morepen Laboratories. Market Cap of Supriya Lifescience is ₹6,862 Crs. While the median market cap of its peers are ₹5,097 Crs.
Is Supriya Lifescience financially stable compared to its competitors?
Supriya Lifescience seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Supriya Lifescience pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Supriya Lifescience latest dividend payout ratio is 4.28% and 3yr average dividend payout ratio is 5.02%
How has Supriya Lifescience allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Supriya Lifescience balance sheet?
Balance sheet of Supriya Lifescience is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Supriya Lifescience improving?
Yes, profit is increasing. The profit of Supriya Lifescience is ₹209 Crs for TTM, ₹188 Crs for Mar 2025 and ₹119 Crs for Mar 2024.
Is the debt of Supriya Lifescience increasing or decreasing?
Yes, The net debt of Supriya Lifescience is increasing. Latest net debt of Supriya Lifescience is -₹78.87 Crs as of Mar-26. This is greater than Mar-25 when it was -₹158.28 Crs.
Is Supriya Lifescience stock expensive?
Yes, Supriya Lifescience is expensive. Latest PE of Supriya Lifescience is 32.82, while 3 year average PE is 26.21. Also latest EV/EBITDA of Supriya Lifescience is 23.07 while 3yr average is 17.07.
Has the share price of Supriya Lifescience grown faster than its competition?
Supriya Lifescience has given better returns compared to its competitors. Supriya Lifescience has grown at ~52.28% over the last 3yrs while peers have grown at a median rate of 20.85%
Is the promoter bullish about Supriya Lifescience?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Supriya Lifescience is 68.3% and last quarter promoter holding is 68.3%.
Are mutual funds buying/selling Supriya Lifescience?
The mutual fund holding of Supriya Lifescience is increasing. The current mutual fund holding in Supriya Lifescience is 1.33% while previous quarter holding is 0.67%.